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IGF systemcontributes significantly tomanyhumanmalignancies. Targeting IGF-I receptor (IGF-IR) has
been reported to be active against several tumors, but particular efficacywas observed only against a
minority of Ewing’s sarcoma patients. Identification of mechanisms of acquired resistance to anti-
IGF-IR agents ismandatory to individualize their use in clinics andoptimize cure costs. In this study,we
compared gene expression profiles of cells made resistant with three different anti-IGF-IR drugs
(human antibodies AVE1642, Figitumumab, or tyrosine kinase inhibitor NVP-AEW541) to highlight
common and distinctive mechanisms of resistance. Among common mechanisms, we identified two
molecular signatures thatdistinguish sensitive fromresistant cells. Annotationanalysis indicated some
common altered pathways, such as insulin signaling,MAPK pathway, endocytosis, andmodulation of
some members of the interferon-induced transmembrane protein family. Among distinctive path-
ways/processes, resistance to human antibodies involves mainly genes regulating neural differentia-
tion and angiogenesis, whereas resistance to NVP-AEW541 is mainly associated with alterations in
genes concerning inflammation and antigen presentation. Evaluation of the common altered path-
ways indicated that resistant cells seemtomaintain intact the IGF-IR internalization/degradation route
of sensitive cells but constantlydown-regulated its expression. In resistant cells, the lossofproliferative
stimulus, normally sustainedby IGF-I/IGF-IR autocrine loop in Ewing’s sarcoma cells, is compensatedby
transcriptional up-regulation of IGF-II and insulin receptor-A; this signaling seems to favor theMAPK
pathway over the v-akt murine thymoma viral oncogene homolog 1 pathway. Overall, complexity of
IGF system requires analytical evaluation of its components to select those patients that may really
benefit from this targeted therapy and support the idea of cotargeting IGF-IR and insulin receptor-A
to increase the efficacy. (Molecular Endocrinology 26: 1603–1616, 2012)
The IGF system contributes significantly to many hu-man malignancies. Both in vitro and in vivo studies
have clearly implicate IGF and their receptors in the reg-
ulation of crucial processes, such as anchorage-indepen-
dent growth, migration, metastasis, and resistance to sev-
eral anticancer agents. The IGF system is composed of
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multiple receptors and ligands (for a review, see Refs. 1,
2). Briefly, there are three ligands (IGF-I, IGF-II, and in-
sulin), four receptors, at least six high-affinity binding
proteins and binding protein proteases. The IGF-I recep-
tor (IGF-IR) shows high level of sequence identity, par-
ticularly within the intracellular kinase domain (84% of
homology), to the insulin receptor (IR). This homology is
important to determine the overlapping but different bi-
ological effects of IGF-IR and IR. Two isoforms of IR are
generated by alternative splicing of exon 11, giving rise to
the exon 11 (IR-B) and exon 11 (IR-A), which lacks
the 12 amino acids of exon 11. The two isoforms are differ-
entially expressed during development, with IR-A prevalent
in fetal tissues and IR-B in adult tissues, particularly liver,
muscle, and adipose tissue. Insulin and IGF bind with high
affinity to their cognate receptor and with lower affinity to
the noncognate receptor, with the exception of IGF-II,
which also binds IR-Awith high affinity (3). Although both
IR and IGF-IR similarly activate phosphatidylinositol 3 ki-
nase and MAPK pathways (4, 5), subtle differences exist in
the recruitment of certain docking proteins and intracellular
mediators. These differences are the basis for the predom-
inant metabolic effects elicited by IR activation and the
predominant mitogenic, transforming, and nonmetabolic
effects elicited by IGF-IR activation (6). Recent findings
have, however, added at least two layers of complexity in
IGF system regulation. The first level of complexity is
related to the documented role of IR in mitogenesis and
cell motility (for detailed review, see Ref. 7). The second is
due to the existence of hybrids between IGF-IR and IR.
These receptors, especially those containing the fetal iso-
form IR-A prevalent in tumors (3), have the interesting
biological characteristic to be activated by both IGF
and insulin and also to activate both IR and IGF-IR -
subunits, thus overcoming specificity in intracellular
signaling pathways. Cross talk between IGF-IR and IR
appears more frequent and more relevant for cancer de-
velopment and progression than we previously thought.
This important fact has implications for therapy. Cur-
rently, most therapeutic agents, human antibodies (HAb)
or tyrosine kinase inhibitors (TKI), have been designed to
specifically target IGF-IR while sparing IR, based on the
concern that cotargeting IR would have lead to unaccept-
able toxicity. However, phase I–III clinical studies with
anti-IGF-IR drugs have clearly indicated modest toxic ef-
fects, with mild and reversible hyperglycemia as the most
common toxicity, but limited effectiveness. Particularly in
Ewing’s sarcoma (EWS), despite the presence of the target
in all tumors and ample preclinical evidence supporting
the potential value of anti-IGF-IR agents, less than 10%
of cases extraordinary responded to this therapy (8, 9).
We and others have recently provided evidences for a
compensatory role of IR-A when IGF-1R is disrupted
(10–12), indicating the relationship between these two
receptors as one mechanism responsible of acquired and
intrinsic resistance to selective anti-IGF-IR therapy.How-
ever, other mechanisms have been described in different
tumors (13–16), and further studies are clearly necessary
to better define patients that may really benefit from an
anti-IGF-IR therapy aswell as to rationalize the use of this
targeted therapy in combination treatments.
In this study, we compared resistance mechanisms for
two specific anti-IGF-IR HAb, the AVE1642 or the CP-
751,871 (Figitumumab), and the anti-IGF-IR TKI NVP-
AEW541. Three EWS cell variants specifically resistant to
each drug have been genetically andmolecularly analyzed
to identify common as well as distinct mechanisms of
acquired resistance, to provide insights to be used for
reversal or prevention of resistance. In addition, we iden-
tified a restricted genetic signature highly associated with
anti-IGF-IR resistance thatmay find application in appro-
priate selection of patients.
Materials and Methods
Drugs
The anti-IGF-IR drugs were kindly provided by: Immuno-
gen (AVE1642 HAb; Waltham, AM), Pfizer (CP-751,871/
Figitumumab; San Diego, CA), and Novartis (NVP-AEW541;
Basel, Switzerland).
Establishment of resistant cells
The EWS TC-71 cell line was recently authenticated (17).
Cells resistant to the anti-IGF-IRHAb AVE1642 and to the TKI
NVP-AEW541 were obtained from TC-71 cell line by exposure
to increasing concentrations of the anti-IGF-IR HAb AVE1642
(up to 10 g/ml) or to the TKI NVP-AEW541 (up to 5 M) for
6 months, as recently described and characterized (11). Simi-
larly, we obtained and here described a new cell line variant
resistant to 100 g/ml of anti-IGF-IR HAb Figitumumab (CP-
751,871) (18). Resistant variants were referred here as TC/AVE
or TC/AEW or TC/CP. All these cell variants were tested for
mycoplasma contamination every 3 months (last control, No-
vember 2011) by PCRMycoplasma detection set (TaKaRa Bio,
Inc., Shiga, Japan). In experimental conditions, cells were main-
tained in standard medium [Iscove’s modified Dulbecco’s me-
dium (IMDM), plus 10% fetal bovine serum (FBS)] lacking
selecting agents for at least 48 h, to avoid effects of direct expo-
sure to HAb or TKI.
In vitro assays
To assess cell growth, MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide) assay (Roche, Indianapolis,
IN) was used according to manufacturer’s instructions. Cells
were plated into 96-well plates (2500 cells/well) in IMDM plus
10% FBS. After 24 h, various concentrations of AVE1642 (1–
100 ng/ml), and vincristine (VCR) (0.01–50 g/ml), NVP-
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AEW541 (0.03–5 M), Figitumumab (0.5–500 g/ml), doxoru-
bicin (DXR) (0.1–3 ng/ml) were added and cells exposed to
these drugs for up to 72 h. Anchorage-independent growth was
determined after seeding 1000 cells/dish in 0.33% agarose (Sea-
Plaque; FMCBioProducts, Rockland,ME) with a 0.5% agarose
underlay (19). IFITM1 expression was transiently silenced by a
pool of three target-specific small interfering RNA (siRNA)
from Santa Cruz Biotechnology, Inc. (San Diego, CA). TC/AVE
or TC/AEW were pretreated with IFITM1 siRNA (50 nM) for
24 h and then exposed to AVE1642 (0.1–10 g/ml) or to NVP-
AEW541 (0.5–5 M) for 48 h. On-TargetPlus NonTargeting
Pool (Dharmacon, Chicago, IL) was used as control.
Reverse transcription-polymerase chain reaction
Total RNA (2 mg) was extracted by TRIzol and reverse tran-
scribed by ThermoScript RT (Invitrogen, Carlsbad, CA) and
Oligo dT primers (Applied Biosystems, Carlsbad, CA). Quanti-
tative real-time PCR was performed on ABI Prism 7900 (Ap-
plied Biosystems) using predesigned TaqMan gene expression
Assay (IGF binding protein-3, Hs00426287_m1) and SYBR
Green PCR Master Mix (Applied Biosystems). Primer Express
software (Applied Biosystems) was used to design appropriate
primers pairs for target genes [Nanog homeobox (Nanog),
octamer-binding transcription factor (OCT) 3/4, IR, IGF-I, IGF-
II, interferon-induced transmembrane protein (IFITM)1, and
IFITM3] as well as for reference gene (glyceraldehyde-3-phos-
phate dehydrogenase) (Supplemental Table 1, published on The
Endocrine Society’s Journals Online web site at http://mend.
endojournals.org). Relative quantitative determination of target
gene levels was performed by comparing the comparative
threshold cycle method (20).
Western blotting and immunoprecipitation
Cell lysates were prepared and processed as previously de-
scribed (19). Membranes were incubated overnight with the
following primary antibodies: anti-IGF-I-R, anti-IR, anti-src
homology 2 domain containing transforming protein (Santa
Cruz Biotechnology, Inc.); antiphospho-Akt (Ser473), anti-
AKT (v-akt murine thymoma viral oncogene homolog 1), an-
tiphospho-glycogen synthetase kinase3 (Ser9), anti-glycogen
synthetase kinase3, and anti-ERK (Cell Signaling Technology,
Beverly, MA); antiphospho-ERK (Tyr202/Tyr204) (Covance,
Princeton, NJ); anti-insulin receptor substrate-1 (Upstate Bio-
technology, Temecula, CA); anti-IFITM1 (Santa Cruz Biotech-
nology, Inc.); and antirabbit or antimouse antibodies conjugated
to horseradish peroxidase (GE Healthcare, Piscataway, NJ) were
used as secondary antibodies. For immunoprecipitation, lysates
were immunoprecipitated as previously described (21).
The phosphorylation status of IR was measured with the
anti-p-IGF-IR(Y1131)/p-IR(Y1146) (Cell Signaling Technol-
ogy) in IR immunoprecipitation.
Neural differentiation
EWS cells were seeded at low density (25,000 cells/dish 60
mm) in standard medium; 96 h later, immunofluorescence anal-
ysis was performed for H neurofilament and -III tubulin
(Sigma, St. Louis, MO), as previously described (22).
IGF-IR internalization
Cells were plated onto 10 g/ml fibronectin-coated glasses
coverslips. After 1 d, cells were starved in binding buffer
[IMDM 2% FBS, 20 mMHEPES (pH 7.4), and 0.1% BSA] with
2% FBS for 1 h; 200 M chloroquine or 20 mM NH4Cl was
added when specified. Afterwards, cells were incubated at 37 C
in the presence of AVE1642HAb (100 ng/ml) or NVP-AEW541
(5 g/ml) for 1–6 h and then fixed in 4% paraformaldehyde.
Cells were permeabilized with 0.1% saponin. IGF-IR was
detected by using HAb AVE1642 and antihuman Alexa Fluor
488-conjugated as secondary antibody. To stain lysosomes,
lysosomal-associated membrane protein 1 (LAMP-1) mono-
clonal antibody (BD Pharmingen, San Diego, CA) was used as
primary antibody, followed by a Cy3 antimouse secondary
antibody (goat antimouse; Molecular Probes, Eugene, OR).
Nuclei were 4,6-diamidino-2-phenylindole stained. Analy-
ses were made by confocal microscope.
Gene expression profiling and bioinformatics
analysis
Cells were profiled by using HG-U133 Plus 2.0 array accord-
ing to manufacturer’s instruction (Affymetrix, Santa Clara,
CA). Two/three independent experiments were performed for
each cell line. Data were normalized and summarized by rma
algorithm, filtered for low expressed genes, and analyzed with
supervised techniques by t test statistics (P  0.05) with Benja-
mini andHochberg (23) correction to reduce false discovery rate
(FDR) and/or by firstly considering fold changes (FC) of at least
2.0 between themean of each compared group.Microarray data
are available at GEO with accession no. GSE34027 (24). Hier-
archical clustering was performed on differentially expressed
genes using Pearson’s correlation inGeneSpring 11.02 software.
KEGG (25) pathways andGeneOntology (26)were analyzed by
MetaCore from GeneGO, Inc. (St. Joseph, MI) and by FatiGO
(http://babelomics.bioinfo.cipf.es/) (27) softwares. Functional
analysis was also performed on normalized data after exclusion
of low-expressed genes with GSEA (www.broadinstitute.org/
gsea/) (28).
Statistical analysis
Differences among means were analyzed using a two-sided
Student’s t test; gene variations were considered significant
when P  0.05.
Results
Cells resistant to anti-IGF-IR agents maintain the
malignant features of parental cells
Starting from the sensitive TC-71 EWS cell line, we
obtained a cell variant (named TC/CP) stably resistant to
100g/mlHAb Figitumumab (CP-751,871) (Supplemen-
tal Fig. 1). TC/CP cells were analyzed in comparison with
parental cell line as well as TC-71 cell variants resistant to
HAb AVE1642 and NVP-AEW541, which were previ-
ously characterized (11). All the three resistant variants
maintained the proliferative and malignant properties of
parental cell line, as shown by similar in vitro growth
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capabilities (Fig. 1A), as well as expression of Oct3/4 and
Nanog, two markers of cell stemness (Fig. 1B). Consider-
ing drug sensitivity, all the three resistant cell variants
showed cross-resistance to the anti-IGF-IR agents (Fig.
1C) and similar levels of sensitivity toward vincristine and
doxorubicin (Fig. 1D), two leader drugs in the treatment
of EWS tumors.
Functional pathways associated with resistance to
anti-IGF-IR agents
Gene expression profile of TC/AVE, TC/AEW, and
TC/CP cells was performed using Affymetrix GeneChip
and compared with that of parental cell lines. Genetic
data were analyzed as summarized in Supplemental Fig. 2
and specified in Materials and Methods. Functional en-
FIG. 1. Biological features of EWS cells resistant to different agents anti-IGF-IR. A, In vitro growth of resistant variants compared with parental cell
lines. Left, Monolayer cell growth was assessed by MTT assay. Right, Anchorage-independent growth. Number of colonies in triplicate plates was
determined after 7 d of growth. Data represent mean values of three independent experiments, and bars represent SE. B, Relative mRNA
expression level of OCT 3/4 and Nanog, two markers of cell renewal and pluripotency, in resistant cell lines. TC-71 parental cells were used as
calibrator (2DDCT  1). C, Cross-resistance to different anti-IGF-IR agents: sensitivity was assessed by MTT assay after 72 h of exposure to either
AVE1642 or CP-751,871 or NVP-AEW541. Columns represent mean values of three independent experiments, and bars represent SE. D, Efficacy of
VCR or DXR in TC/CP, TC/AEW, and TC/AVE. Cell growth was assessed by MTT assay after 72 h of exposure to VCR or DXR and shown as a
percentage of survival. Data represent mean values of three independent experiments and bars represent SE.
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richment analysis by GSEA of the three resistant cell lines
compared with sensitive parental cells identified a signif-
icant (P 0.05 and FDR 0.25) modulation of 33 com-
mon pathways (Table 1). We investigated in detail the
most modulated pathways: MAPK kinase pathway (P 
6.54E3), insulin signaling (P  1.29E2), and endocy-
tosis (P  1.00E4). Concerning insulin pathway, we
have previously demonstrated a switch from a canonical
IGF-I/IGF-IR-mediated pathway to the alternative IGF-II/
IR-A signaling in cells resistant to HAb AVE1642 and
NVP-AEW541 (11). Here, we confirm that also the TC/
CP-resistant cells show up-regulation at transcriptional
and protein level of IR-A (Fig. 2) as well as up-regulation
of IGF-II, without significant changes in IGF-I and IGF
binding protein-3 expression (Supplemental Fig. 3). In
parallel, cells show down-regulation of IGF-IR (Fig. 2), a
feature that may be due to alterations in endocytosis/
degradation of the receptor or may simply reflect the
mechanisms of action of anti-IGF-IR drugs. Either
AVE1642 or Figitumumab HAb was reported to induce
internalization and degradation of IGF-IR (29, 30),
whereas no information is available for NVP-AEW541.
We followed intracellular IGF-IR trafficking upon HAb
AVE1642 or NVP-AEW541 treatments by immunofluo-
rescence. In TC-71-untreated cells, IGF-IR mainly local-
izes at cell surface (Fig. 3A). Internalization route was
tracked by colocalization of IGF-IR with the known pro-
tein marker LAMP-1 that stains lysosomes (Fig. 3A). Af-
ter 1 h of treatment with AVE1642 HAb, IGF-IR was
TABLE 1. Pathways significantly modulated (P  0.05 and FDR  0.25) in EWS-resistant vs. EWS-sensitive cells
according to GSEA analysis with Kegg database
NAME Size ES P value FDR
MAPK_SIGNALING_PATHWAY 134 0.14 0.00654 0.04
INSULIN_SIGNALING_PATHWAY 78 0.168 0.0129 0.06
ENDOCYTOSIS 91 0.185 0.0001 0.03
VEGF_SIGNALING_PATHWAY 46 0.193 0.0383 0.14
NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY 58 0.203 0.0108 0.06
RENAL_CELL_CARCINOMA 41 0.206 0.0301 0.15
CHEMOKINE_SIGNALING_PATHWAY 70 0.214 0.0001 0.04
GNRH_SIGNALING_PATHWAY 44 0.214 0.0336 0.11
TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY 43 0.215 0.0262 0.12
ERBB_SIGNALING_PATHWAY 48 0.219 0.011 0.08
FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS 45 0.233 0.00518 0.06
PANCREATIC_CANCER 47 0.244 0.00266 0.03
GLYCEROPHOSPHOLIPID_METABOLISM 28 0.251 0.0362 0.15
ACUTE_MYELOID_LEUKEMIA 36 0.252 0.00535 0.06
ANTIGEN_PROCESSING_AND_PRESENTATION 29 0.256 0.0234 0.14
CELL_ADHESION_MOLECULES_CAMS 46 0.257 0.0027 0.03
PATHOGENIC_ESCHERICHIA_COLI_INFECTION 28 0.27 0.0227 0.12
T_CELL_RECEPTOR_SIGNALING_PATHWAY 59 0.283 0.0001 0.01
FC_EPSILON_RI_SIGNALING_PATHWAY 38 0.286 0.0001 0.03
B_CELL_RECEPTOR_SIGNALING_PATHWAY 42 0.3 0.0001 0.01
ENDOMETRIAL_CANCER 32 0.309 0.00494 0.03
COLORECTAL_CANCER 40 0.313 0.0001 0.02
N_GLYCAN_BIOSYNTHESIS 21 0.342 0.00454 0.05
TYPE_II_DIABETES_MELLITUS 20 0.35 0.00948 0.05
DORSO_VENTRAL_AXIS_FORMATION 14 0.368 0.032 0.12
TYPE_I_DIABETES_MELLITUS 12 0.399 0.0256 0.13
STEROID_BIOSYNTHESIS 16 0.403 0.0112 0.04
BIOSYNTHESIS_OF_UNSATURATED_FATTY_ACIDS 14 0.464 0.0001 0.03
NITROGEN_METABOLISM 7 0.499 0.0319 0.12
GLYCOSAMINOGLYCAN_BIOSYNTHESIS_KERATAN_SULFATE 6 0.512 0.0413 0.18
GRAFT_VERSUS_HOST_DISEASE 10 0.516 0.00462 0.04
AUTOIMMUNE_THYROID_DISEASE 11 0.524 0.00444 0.03
ALLOGRAFT_REJECTION 10 0.608 0.0001 0.01
Pathways are ordered on the basis of enrichment score (ES) (lower ES indicates higher significance). Pathways with less than 5 or more than 200
genes were excluded because considered meaningless or nonspecific, respectively.
FIG. 2. IGF-IR/IR modulation in resistant variants compared with
parental cells. Protein expression levels of receptors in resistant
variants. Blots are representative of two independent experiments.
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completely internalized and contained in perinuclear
round-shaped subcellular compartments. It colocalized
largely with LAMP-1, suggesting that it has been routed
to lysosomes. After a 6-h treatment, IGF-IR levels were
significantly reduced due to receptor degradation, as ob-
served also by western blotting analysis (Fig. 3B). To con-
firm that IGF-IR degradation was mainly dependent on
the lysosomal pathway, we used two inhibitors of lysoso-
mial-dependent degradation, chloroquine and NH4Cl
(31). Receptor degradation was indeed prevented, as in-
dicated by the accumulation of IGF-IR in large perinu-
clear compartments that colocalized with LAMP-1 (Fig.
3A) aswell as by the restoring of IGF-IR protein level (Fig.
3B). Similar effects were observed in TC/AVE cells. Al-
though weaker at baseline conditions, IGF-IR expression
became more marked after combined treatment of resis-
tant cells with AVE1642 HAb and lysosomal inhibitors
(Fig. 3B). This indicates that AVE1642 HAb similarly
induces internalization and degradation of IGF-IR in sen-
sitive and resistant cells. In contrast, comparative analysis
FIG. 3. Different IGF-IR route in resistant cells compared with parental cells. A, Fluorescence evaluation of IGF-IR internalization/degradation in
TC-71 cells, upon AVE1642 or NVP-AEW541 treatment, as described in Materials and Methods. LAMP-1 staining was used as lysosome marker;
Chl and NH4Cl were used as lysosome function inhibitors. Scale bars, 50 m. B, Modulation of IGF-IR protein levels in TC-71, TC/AVE, and
TC/AEW cells upon 6 h of treatment with AVE1642 or NVP-AEW541 in combination or not with the lysosomal inhibitors (Chl and NH4Cl). Tubulin
was used as loading control. Blots are representative of two independent experiments.
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with NVP-AEW541 indicates that treatments with the
TKI lead to receptor internalization but not to IGF-IR
degradation. After a 6-h treatment, receptor localizes in
discrete foci, with a good LAMP-1 colocalization (Fig.
3A), but no reduction of IGF-IR levels is observed (Fig. 3,
A and B). Cotreatment with chloroquine or NH4Cl does
not modify the intracellular localization of the receptor
(Fig. 3A) nor its protein expression levels (Fig. 3B). After
a 20-h treatment with the TKI, receptor relocalizes at cell
membrane (Supplemental Fig. 4), possibly through recy-
cling, in agreement with the idea that NVP-AEW541 in-
duces internalization but not degradation of IGF-IR. Sim-
ilar effects were observed in TC/AEW-resistant cells.
Exposure to lysosome inhibitors did not modify the ex-
pression of IGF-IR (Fig. 3B), indicating also in this case no
substantial alteration in the IGF-IR internalization/degra-
dation processes between resistant and sensitive cells. Ex-
posure to HAb AVE1642 or to TKI NVP-AEW541 in-
duces inhibition of MAPK and AKT pathway in sensitive
but not in resistant cells, as expected (data not shown).
Thus, although in TC/AVE cells, the lower expression of
IGF-IR compared with parental cell line may reflect the
constant and higher activation of the endocytosis route by
the antibody, the IGF-IR down-regulation in TC/AEW
cells is attributable to other mechanisms, likely involving
decreased IGF-IR transcription as previously shown (11).
Concerning IR signaling, we did not observe remarkable
differences among the three resistant cell variant with
respect to IR-A phosphorylation status (Fig. 4A). Regard-
ing MAPK pathway, functional analysis highlighted that
all the genes participating to MAPK signaling are com-
monly up-regulated in resistant cells (Supplemental Fig.
5), whereas genes of the AKT pathway have a more vari-
able behavior. Indeed, a constitutive hyperphosphoryla-
tion of ERK1/2 was observed in all the three resistant cell
variants as compared with the parental cells (Fig. 4B),
whereas AKT pathway activation seems more variable in
resistant cells, being reduced in TC/CP and TC/AEW but
slightly increased in TC/AVE (Fig. 4B). Taken together,
these data indicate that all three resistant cell lines develop
an unbalanced activation of IR-A-mediated intracellular
pathways that favors the MAPK pathway over the AKT
pathway in sustaining malignant features and resistance
to anti-IGF-IR agents.
Common gene signatures associated with
resistance to anti-IGF-IR agents
Supervised analysis by t test corrected for FDR was
used for the detection of differentially expressed genes in
cells sensitive or resistant to anti-IGF-IR drugs. It pointed
out a genetic signature of 191 probes (91 up-regulated
and 100 down-regulated), corresponding to 160 unique
well-characterized genes (for complete list of probes, see
Supplemental Table 2). Clustering algorithm analysis per-
formed with this signature correctly distinguishes resis-
tant cells (Fig. 5A). Top regulated genes are shown in
Fig. 5A, indicating alterations in genes functionally as-
sociated with cholesterol biosynthesis and lipid metab-
olism, inflammation (up-regulated genes), or with cy-
toskeleton remodeling and extracellular matrix interaction
(down-regulated genes). Involvement of these functionswas
pointed out also by annotation analysis performed by Ge-
neGO Software (data not shown).
To further highlight common mechanisms that may
cause and/or sustain resistance to different anti-IGF-IR
therapies, we also analyzed each of the three cell variants
separately in comparison with the parental cell line. FC
evaluation (2 FC) and t test analysis (P  0.05) ended
upwith the definition of selective gene expression profiles
associated with resistance toHAbAVE1642 (signature of
562 probes), HAb CP-751,871 (signature of 385 probes),
and NVP-AEW541 (signature of 166 probes) (detailed
lists of genes reported in Supplemental Tables 3–5). Over-
FIG. 4. IGF system modulation in resistant variants compared with
resistant cells. A, Phosphorylation level of IR-A between resistant cells.
Total protein lysates (500 g) were immunoprecipitated (IP) with IR
polyclonal antibody and then probed (Western blotting) by anti-p-IGF-
IR(Y1131)/p-IR(Y1146). B, Activation status of IGF-IR/IR signaling
mediators in parental and resistant cells. Total proteins were used as
controls. Blots are representative of two independent experiments. IRS,
Insulin receptor substrate; Shc, src homology 2 domain containing
transforming protein; GSK, glycogen synthase kinase.
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lapping of these three signatures indicated a core group of
35 probes that appeared to be in common to the three
resistances (Fig. 5B). This restricted signature was still
able to clusterize the three resistant cell variants in com-
parison with parental cell line (Fig. 5B). Among these 35
probes, 27 were also included in the common 191-probe
signature and are reported in Table 2. Among most mod-
ulated genes, IFITM3 and ubiquitin-like modifier [ISG
FIG. 5. Common gene signatures associated with resistance to anti-IGF-IR agents. A, Cluster analysis performed with the 191 probes differentially
expressed between resistant variants vs. parental TC-71 cell line (Supplemental Table 2). The most up-regulated and down-regulated genes with
their relative FC, fold changes, are shown. B, Venn diagram shows common genes to the three distinctive signatures that emerged from separate
microarray analysis of each resistant cell line vs. parental TC-71 (Supplemental Tables 3–5); 35 probes were in common and cluster analysis
distinguished resistant cell lines. C, Network analysis on the 35 probes pointed out a common network based on interferon-induced
transmembrane molecule IFITM3. Its up-regulation, together with that of IFITM1, was confirmed in resistant variants by quantitative RT-PCR. D,
Reversion of resistance to anti-IGF-IR therapies by IFITM1 knockdown. Silencing of IFITM1 in TC/AVE and TC/AEW cell lines was achieved after 24 h
of transfection of siIFITM1 (50 nM) or scrambled control siRNA (50 nM); -actin was used as loading control. Transfected cells were treated as
described in Materials and Methods. Cell survival was shown as a percentage of growth respect to untreated control. Data represent mean values
of two independent experiments, and bars represent SE.
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(interferon-stimulated gene) 15] were up-regulated,
whereas glutamyl aminopeptidase A (ENPEP), endothe-
lin receptor type A (EDNRA), and solute carrier family
(SLC)7 member 2 were strongly down-regulated. Com-
parative network analysis highlighted a common network
based on IFITM gene family (Fig. 5C). Increased expres-
sion of the IFITM family members IFITM1 and IFITM3
was validated by RT-PCR in resistant cell lines (Fig. 5C),
thus identifying another common circuit related to
IGF-IR resistance. Silencing of IFITM1 by short hairpin
RNA technology supported its functional role in mediat-
ing IGF-IR resistance. TC/AVE or TC/AEW were pre-
treated with IFITM1 siRNA for 24 h and then exposed to
AVE1642 or toNVP-AEW541 for 48 h. As shown, in Fig.
5D, when cells are deprived of IFITM1 their sensitivity to
anti-IGF-IR agents is partially recovered.
Differential and specific gene profiles associated
with resistance to anti-IGF-IR drugs
In addition to identifying shared resistance mecha-
nisms, we were also interested in pointing out possible
mechanisms/pathways of resistance unique to the two
types of IGF-IR inhibitors (HAb vs. TKI). Functional an-
notation analysis of the gene expression profiles specifi-
cally associated with resistance to the three agents (de-
tailed lists of genes reported in Supplemental Tables 3–5)
indicated that diverse pathways/processes were modu-
lated in cells resistant to anti-IGF-IR HAb as compared
with cells resistant to the TKI NVP-AEW541. In particu-
lar, either GeneGO (Fig. 6A) or FatiGO softwares (Fig.
6B) pointed out that resistance to HAb involves mainly
genes regulating neural differentiation and angiogenesis,
whereas resistance to NVP-AEW541 is mainly associated
TABLE 2. Thirty-five probes with significant differential expression in all three cell lines
Probe Symbol Description
FC TC/AVE
vs. TC-71
FC TC/AEW
vs. TC-71
FC TC/CP
vs. TC-71
204783_ata MLF1 Myeloid leukemia factor 1 4.1 4.4 2.5
217867_x_ata BACE2 -Site APP-cleaving enzyme 2 3.7 2.7 3.2
1554250_s_ata TRIM73 Tripartite motif-containing 73 3.7 2.7 2.8
217080_s_ata HOMER2 Homer homolog 2 (Drosophila) 3.2 2.2 2.5
230896_ata BEND4 BEN domain-containing 4 3.1 3.3 3.1
233030_ata PNPLA3 Adiponutrin 2.8 3.2 3.7
220675_s_ata PNPLA3 Adiponutrin 2.8 3.1 3.8
1554334_a_ata DNAJA4 DnaJ (Hsp40) homolog, subfamily A, member 4 2.8 2.3 3
226912_ata ZDHHC23 Zinc finger, DHHC-type-containing 23 2.6 2.8 2.8
212203_x_ata IFITM3 Interferon-induced transmembrane protein 3 (1-8U) 2.3 2.6 2.1
235099_at CMTM8 CKLF-like MARVEL transmembrane domain-containing 8 2.1 3.8 4.2
205483_s_ata ISG15 ISG15 ubiquitin-like modifier 2.1 2.5 2.3
231213_ata PDE1A Phosphodiesterase 1A, calmodulin dependent 2.1 2.2 2.3
222923_s_ata KCNE3 Potassium voltage-gated channel, Isk-related family,
member 3
2.2 2.4 2.8
222922_ata KCNE3 Potassium voltage-gated channel, Isk-related family,
member 3
2.3 2.4 2.5
236234_ata PDE1A Phosphodiesterase 1A, calmodulin dependent 2.6 2.4 2.4
202712_s_ata CKMT1A Creatine kinase, mitochondrial 1A 3.1 2.3 2.4
1569648_ata DACT2 Dapper, antagonist of -catenin, homolog 2 (Xenopus
laevis)
3.4 2.6 3
217553_ata MGC87042 STEAP family protein MGC87042 3.4 3.2 3.2
61734_ata RCN3 Reticulocalbin 3, EF-hand calcium-binding domain 4.1 3 2.6
219837_s_at CYTL1 Cytokine-like 1 4.5 2.1 2.9
219464_ata CA14 Carbonic anhydrase XIV 4.9 3.2 3
202465_at PCOLCE Procollagen C-endopeptidase enhancer 5.1 2.3 2.6
204818_ata HSD17B2 Hydroxysteroid (17-) dehydrogenase 2 6.3 7.9 6.2
204464_s_ata EDNRA Endothelin receptor type A 7.4 3.1 4.6
206632_s_ata APOBEC3B Apolipoprotein B mRNA editing enzyme, catalytic
polypeptide-like 3B
7.6 3.8 3.5
204345_ata COL16A1 Collagen, type XVI,  1 7.8 6.5 6.7
225516_at SLC7A2 Solute carrier family 7, member 2 8.2 2.1 2.6
213479_at NPTX2 Neuronal pentraxin II 15.4 2.4 4.9
220786_s_ata SLC38A4 Solute carrier family 38, member 4 16.2 7.8 9.8
213847_ata PRPH Peripherin 16.8 11.7 12.4
204844_at ENPEP Glutamyl aminopeptidase (aminopeptidase A) 17.5 2.5 2.1
All probes have same modulation in all three experiments. Three probes (1554220_a_at, 237226_at, and 228045_at) match no coding regions
and were excluded from the table; the first probe was up-regulated in resistance cells, whereas the remaining two probes were down-regulated.
a Probes that were also identified in previous signature of 191 probes.
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with alterations in genes concerning inflammation and
antigen presentation as well as in stress responses. Con-
sistently, we observed inhibition of neural differentiation
in TC/CP and TC/AVE cells compared with TC/AEW or
TC-71 cells, according to the expression of -III tubulin
and 200-K neurofilament, two specific markers of neural
differentiation (Fig. 6C).
Discussion
Several experimental and clinical evidences now clearly
indicate that, in addition to the IGF-IR, also the IR is
involved in cancer (32). The functional specificity of in-
sulin/IR signaling is in fact changed in cancer cells because
of the predominant production of isoform A (IR-A) that
FIG. 6. Distinctive processes associated with resistance to different anti-IGF-IR drugs (HAb vs. TKI). Functional annotation analysis of the three
distinctive signatures that discriminate each resistant cell line from the parental TC-71 (Supplemental Tables 3–5) by GeneGO (A) or FatiGO (B)
identified the mostly significantly modulated functions. Cells resistant to HAb mainly showed modulation of genes related to neuronal
differentiation, angiogenesis, and cell adhesion, whereas cell resistant to TKI are more characterized by modulation of genes associated with
immunoresponse and antigen presentation. C, Specific inhibition of neural differentiation in cells resistant to anti-IGF-IR HAb. Neurofilament (H-
NF) and -III tubulin expression was evaluated in cells maintained in standard culture conditions. Representative photomicrographs are shown for
sensitive and resistant variants. Scale bars, 50 m.
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has increased binding affinity for IGF, enhanced hybrid
receptor formation between IR and IGF-IR, and auto-
crine and/or paracrine IGF production. However, due to
concerns on toxicity and possible development of hyper-
glycemia because of the high homology between IGF-IR
and IR, IR has not been considered as a therapeutic target
in cancer, and the initial choice has been the development
of highly selective anti-IGF-IR agents. Single-agent activ-
ity has been reported particularly in EWS, but only a
minority of patients really benefit from this targeted ther-
apies, thus prompting the scientific community to identify
the mechanisms of native and acquired resistance to these
agents to individualize their use in clinics. Because tumor
cells exhibit a high degree of signaling plasticity, which
can contribute to adaptive survival in the presence of a
receptor inhibitor, we compared gene expression profiles
of cells made resistant to three different anti-IGF-IR drugs
(the HAb AVE1642, Figitumumab, or the TKI NVP-
AEW571) to highlight common and distinctive mecha-
nisms of resistance. We identified two molecular signa-
tures, one of 191 probes and one more restricted of 35
probes that perfectly distinguish sensitive from resistant
cells. The annotation analysis indicated some common
altered pathways, mainly related to insulin signaling,
MAPK pathway, endocytosis, and dysregulation of the
interferon system. Because one interesting common fea-
ture about the antibodies directed against IGF-IR is their
ability to bind and down-regulate IGF-IR level through
receptor-mediated endocytosis (30, 33), we explored pos-
sible alterations in the IGF-IR endocytosis processes. En-
docytosis is tightly related with signaling transduction,
modulating and/or sustaining it (34). In EWS cells,
IGF-IR is internalized upon ligand binding, and this pro-
cess, which is dependent on either clathrin-mediated or
raft/caveolar endocystosis, is important for signaling (35).
Here, we show that resistant cells seem to maintain
intact the IGF-IR internalization/degradation route of
sensitive cells. However, down-regulation of IGF-IR is
a common feature of cells resistant to anti-IGF-IR
agents. Most likely, in cells resistant to anti-IGF-IR
HAb, this may rely on higher functioning of the lyso-
somial degradative pathway, which enhances the over-
all down-regulation of the receptor, whereas this pro-
cess is only partially observed in cells resistant to the
TKI NVP-AEW571, which retain only the ability to
internalize the receptor but not to route it to degrada-
tion. In these cells, the down-regulation of IGF-IR
seems to be due to limited transcription of IGF-IR (11).
Whether or not, in analogy with the well-studied EGF
receptorial model (36), this may depend on the existence
of a specific ubiquitination code that, in turns, determines
the receptor fate upon different stimulation, it will be the
subject of future biological studies. In any case, from a
practical point of view, the loss of proliferative stimulus,
normally offered in EWS cells by IGF-IR constantly acti-
vated by IGF-I autocrine production, resulted compen-
sated in resistant cells by the switch to IGF-II/IR-A depen-
dency. In this article, we extended our previous
observations (11) and confirmed that whenever EWS cells
are exposed to a truly specific anti-IGF-IR agent, either
HAb or TKI, they may adapt by inducing compensatory
activation of an IR-A-dependent pathway. Transcrip-
tional up-regulation of IR-A and IGF-II is thus a common
mechanism of resistance to anti-IGF-IR agents in EWS. In
addition, we observed common up-regulation of all the
major mediators of MAPK/ERK pathway in the three
resistant variants, in keeping with the maintenance of
growth abilities and stemness features of parental cells.
Interestingly, Giudice et al. (37) have recently found a
higher rate of endocytosis of IR-A, compared with IR-B,
the isoform associated to metabolic functions of insulin,
and have correlated these differences with preferential
ERK1/2 response to insulin in cells expressing IR-A in
contrast to preferential AKT response to insulin in cells
expressing IR-B. The higher IGF-IR endocytosis/degrada-
tion that we observed in resistant cells may thus be re-
sponsible for their preferential activation of ERK1/2, be-
cause previous findings have shown that long-term cell
exposure to AVE1642 resulted in endocytosis of the IR
present in lipid rafts along with IGF-IR (33). In addition,
using R-/IR-A cells, which represent a suitable model to
study the effect of IGF on IR-A, Sacco et al. (38) found
that IGF-II elicits a peculiar signaling pattern character-
ized by high ERK1/2 response in contrast to lower AKT
activation compared with insulin. The compensatory role
of MAPK signaling after blockage of IGF-IR was also
recently highlighted when EWS cells were exposed to the
anti-IGF-IR R1507 HAb (39), further supporting the use
of MAPK inhibitors as adjuvant agents to overcome
resistance.
Thanks to the exclusive expression of the isoform A of
IR in EWS cells (11), together with the low/absent expres-
sion of IGF-IR in resistant variants, EWS may be consid-
ered a suitable model to study the differential effects of
IGF-II compared with insulin. This model may also be
exploited to clarify mechanisms by which IR-A overex-
pression and autocrine/paracrine production of ligands
may contribute to the activation of the IGF system in
cancer. This seems to be a crucial aspect either to define
biomarkers for individualizing this targeted therapy or
for a better understanding of the IGF system, which be-
sides influencing cancer growth risk (40) greatly modu-
lates cancer cell response to conventional and new drugs
(41, 42). In fact, depending on receptor subtype expres-
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sion and IGF-II vs. IGF-I local availability, a variety of
conditions may be envisaged. For instance, if IR-A and
IGF-IR are concomitantly overexpressed and IGF-I and
IGF-II are present in similar molar concentrations, IGF-I
will mostly signal through IGF-IR and hybrid receptors,
and IGF-II through IR-A, due to their different affinities
to cognate receptors. However, if local IGF concentration
is in favor of one of the two ligands, interactions with
receptors may change. Besides considering the ratio IR/
IGF-IR (10–12), it is also mandatory to precisely evaluate
expression of ligands. As we have previously shown (11),
the two receptors are not equal in sustaining cell prolif-
eration. In a Ewing’s cell line producing only IGF-I, and in
which the expression of IGF-IR and IR is similar, the
silencing of IR-A hasmore limited effects than silencing of
IGF-IR on proliferation. It is only when the cells started to
produce IGF-II that the proliferative stimulus of IR-Awas
equal to that of IGF-IR. This means that differences be-
tween IR-A and IGF-IR effects may be due to a modula-
tion of the amplitude of the signal created by the specific
ligand-receptor interaction (43) and that quantitative
analysis of receptor should go along with that of ligands
to predict responses to therapy.
Several other papers have previously reported that ex-
pression of IGF-IR itself or other IGF system mediators
correlate with response to IGF-IR blockade (13, 44–47).
However, each of these papers supported one or the other
mediator as predictive biomarker. Instead, our message is
that, due to the complex cross talk between the different
components of IGF system, all the players should be eval-
uated and monitored individually before planning treat-
ments. As stated by Baserga in his review (48), customiz-
ing the targeting of IGF system seems to be a strict
requirement for future clinical studies. Technology is now
making this possible. For example, only patients with
IR:IGF-IR and IGF-I:IGF-II ratios in favor of IGF-IR and
IGF-I should be treated with anti-IGF-IR agents. For the
others, that include tumors with aberrant expression of
IGF-II, such as Wilms tumors, hepatocellular cancers,
rhabdomyosarcoma, and osteosarcoma, dual inhibitors
should be preferred.
Together with activation of IR-A/IGF-II signaling, we
identified in modulation of somemembers of IFITM fam-
ily another common mechanism of resistance to anti-
IGF-IR agents. IFITM genes are still poorly studied mol-
ecules that serve different functions in different tumors,
and whose exact role in tumorigenesis is complex (for a
review, see Ref. 49). Although deeper studies are neces-
sary, it is intriguing that these molecules have been found
to be associated with resistance to several other antican-
cer drugs, such as interferon, radiotherapy, and drugs that
target growing cells.We have also previously documented
an increase in IFITMwhen EWS cells became resistant to
Yondelis (50). Besides a role in the control of proliferation
and cell adhesion, new functions have been recently iden-
tified that are related to cell differentiation and innate
immunity. Interestingly, gene expression profiling data of
our resistant cells indicated distinctive modulation in
genes associated with antigen presentation and interactions
with immune system for cells resistant to the TKI inhibitor
NVP-AEW541, whereas modulations of genes associated
with cytoskeleton, mesenchymal-epithelial transition, and
neural differentiation appear to bemore pronounced in cells
resistant to HAb anti-IGF-IR. Whether and how these pro-
cessesmaybe related todifferent expressionandmodulation
of IFITM proteins, which serve different functions in differ-
ent cellular contexts,will be the subject of future studies, but
we still have to include IFITM proteins in the group of mol-
ecules that may have a crucial role in modulating drug
resistance.
In conclusion, although the IGF system clearly remains
an important therapeutic target, it is becoming clear that the
complexity of this pathway requires analytical evaluation of
its components to better select the patients and guide indi-
vidualized treatment combination. Our data provide evi-
dences on common as well as distinctive mechanisms of
action and resistance to truly specific anti-IGF-IRagents and
support the idea that using small molecules that cotarget
IGF-IR and IR-A, such as TKI OSI-906 (12), or antibodies
that target IGF-I and IGF-II, such as MEDI-573 (51), may
provide new impetus for a more effective application of this
targeted therapy.
Acknowledgments
We thank Cristina Ghinelli and Alba Balladelli for their help in
editing the manuscript.
Address all correspondence and requests for reprints to:
Katia Scotlandi, Via di Barbiano 1/10, 40136 Bologna, Italy.
E-mail: katia.scotlandi@ior.it.
This work was supported by an Italian Association for Can-
cer Research grant (IG10452 to K.S.; MFAG11584 to C.G.;
10625/2012 to A.B.), the Italian Ministry of Health The Italian
Ministry of Health 2009: 1628/2010; (to K.S.; 5‰ contribu-
tions to Rizzoli Institute), and the Italian Ministry of Research
and Instruction Grant PRIN2009 cod.SFC2EK.
Disclosure Summary: The authors have nothing to disclose.
References
1. PollakM 2007 Insulin-like growth factor-related signaling and can-
cer development. Recent Res Cancer Res 174:49–53
2. Samani AA, Yakar S, LeRoith D, Brodt P 2007 The role of the IGF
1614 Garofalo et al. Resistance to Anti-IGF-IR Therapy Mol Endocrinol, September 2012, 26(9):1603–1616
Downloaded from https://academic.oup.com/mend/article-abstract/26/9/1603/2614994
by IEO - European Institute of Oncology user
on 23 February 2018
system in cancer growth and metastasis: overview and recent in-
sights. Endocr Rev 28:20–47
3. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A,
Goldfine ID, Belfiore A, Vigneri R 1999 Insulin receptor isoform A,
a newly recognized, high-affinity insulin-like growth factor II recep-
tor in fetal and cancer cells. Mol Cell Biol 19:3278–3288
4. Laviola L, Perrini S, Cignarelli A, Natalicchio A, Leonardini A, De
Stefano F, CuscitoM, De FazioM,Memeo V, Neri V, Cignarelli M,
Giorgino R, Giorgino F 2006 Insulin signaling in human visceral
and subcutaneous adipose tissue in vivo. Diabetes 55:952–961
5. Laviola L, Natalicchio A, Giorgino F 2007 The IGF-I signaling
pathway. Curr Pharm Des 13:663–669
6. Siddle K 2011 Signalling by insulin and IGF receptors: supporting
acts and new players. J Mol Endocrinol 47:R1–R10
7. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R 2009 Insulin
receptor isoforms and insulin receptor/insulin-like growth factor
receptor hybrids in physiology and disease. Endocr Rev 30:586–
623
8. Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM,
Paccagnella ML, Batzel GN, Yin D, Pritchard-Jones K, Judson I,
Worden FP, Gualberto A, Scurr M, de Bono JS, Haluska P 2010
Safety, pharmacokinetics, and preliminary activity of the anti-
IGF-1R antibody figitumumab (CP-751,871) in patients with sar-
coma and Ewing’s sarcoma: a phase 1 expansion cohort study.
Lancet Oncol 11:129–135
9. Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla
SP, Toner GC,Maki RG,Meyers PA, Chugh R, Ganjoo KN, Schue-
tze SM, Juergens H, LeahyMG, Geoerger B, Benjamin RS, Helman
LJ, Baker LH 2011 R1507, a monoclonal antibody to the insulin-
like growth factor 1 receptor, in patients with recurrent or refrac-
tory Ewing sarcoma family of tumors: results of a phase II sarcoma
alliance for research through collaboration study. J Clin Oncol 29:
4541–4547
10. Ulanet DB, Ludwig DL, Kahn CR, Hanahan D 2010 Insulin recep-
tor functionally enhances multistage tumor progression and con-
veys intrinsic resistance to IGF-1R targeted therapy. ProcNatl Acad
Sci USA 107:10791–10798
11. Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL,
Astolfi A, Pandini G, López-Guerrero JA, Schaefer KL, Belfiore A,
Picci P, Scotlandi K 2011 Efficacy of and resistance to anti-IGF-1R
therapies in Ewing’s sarcoma is dependent on insulin receptor sig-
naling. Oncogene 30:2730–2740
12. Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N,
Rosenfeld-Franklin M, Lerner L, Chiu MI, Wild R, Epstein D,
Pachter JA, Miglarese MR 2010 Compensatory insulin receptor
(IR) activation on inhibition of insulin-like growth factor-1 recep-
tor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.
Mol Cancer Ther 9:2652–2664
13. Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM,
Reeves K, Chen J, Robinson D, Li A, Lee FY, Gottardis MM, Clark
E, Helman L, Attar RM, Dongre A, Carboni JM 2009 The mech-
anisms of differential sensitivity to an insulin-like growth factor-1
receptor inhibitor (BMS-536924) and rationale for combining with
EGFR/HER2 inhibitors. Cancer Res 69:161–170
14. Haluska P, Carboni JM, TenEyck C, Attar RM, Hou X, Yu C,
Sagar M, Wong TW, Gottardis MM, Erlichman C 2008 HER
receptor signaling confers resistance to the insulin-like growth
factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther
7:2589–2598
15. Gualberto A, Dolled-Filhart M, Gustavson M, Christiansen J,
Wang YF, HixonML, Reynolds J, McDonald S, Ang A, RimmDL,
Langer CJ, Blakely J, Garland L, Paz-Ares LG, Karp DD, Lee AV
2010 Molecular analysis of non-small cell lung cancer identifies
subsets with different sensitivity to insulin-like growth factor I re-
ceptor inhibition. Clin Cancer Res 16:4654–4665
16. Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoël MJ, Fartoux
L, Venot C, Bladt F, Housset C, Rosmorduc O 2009 Insulin-like
growth factor-1 receptor inhibition induces a resistance mechanism
via the epidermal growth factor receptor/HER3/AKT signaling
pathway: rational basis for cotargeting insulin-like growth factor-1
receptor and epidermal growth factor receptor in hepatocellular
carcinoma. Clin Cancer Res 15:5445–5456
17. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S,
Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH,
Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PC,
Buerger H, Aigner T, Gabbert HE, Poremba C 2010 Molecular
characterization of commonly used cell lines for bone tumor re-
search: a trans-European EuroBoNet effort. Gene Chromosome
Cancer 49:40–51
18. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM,
Miller PE, TengowskiMW,Wang F, Gualberto A, Beebe JS,Moyer
JD 2005 Combination therapy enhances the inhibition of tumor
growth with the fully human anti-type 1 insulin-like growth factor
receptor monoclonal antibody CP-751,871. Clin Cancer Res 11:
2063–2073
19. Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini
S, Croci S, Perdichizzi S, Zambelli D, SerraM,García-Echeverría C,
Hofmann F, Picci P 2005 Antitumor activity of the insulin-like
growth factor-I receptor kinase inhibitor NVP-AEW541 in muscu-
loskeletal tumors. Cancer Res 65:3868–3876
20. Ginzinger DG 2002 Gene quantification using real-time quantita-
tive PCR: an emerging technology hits the mainstream. Exp Hema-
tol 30:503–512
21. Garofalo C, Sisci D, Surmacz E 2004 Leptin interferes with the
effects of the antiestrogen ICI 182,780 inMCF-7 breast cancer cells.
Clin Cancer Res 10:6466–6475
22. Rocchi A,ManaraMC, SciandraM, Zambelli D, Nardi F, Nicoletti
G, Garofalo C, Meschini S, Astolfi A, Colombo MP, Lessnick SL,
Picci P, Scotlandi K 2010 CD99 inhibits neural differentiation of
human Ewing sarcoma cells and thereby contributes to oncogene-
sis. J Clin Invest 120:668–680
23. Benjamini YH, Hochberg Y 1995 Controlling the false discovery
rate: a practical and powerful approach to multiple testing. J R Stat
Soc 57:289–300
24. Edgar R, Domrachev M, Lash AE 2002 Gene expression omnibus:
NCBI gene expression and hybridization array data repository. Nu-
cleic Acids Res 30:207–210
25. KanehisaM, Goto S 2000 KEGG: Kyoto encyclopedia of genes and
genomes. Nucleic Acids Res 28:27–30
26. AshburnerM, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM,
Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP,
Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE,
Ringwald M, Rubin GM, Sherlock G 2000 Gene ontology: tool for
the unification of biology. The gene ontology consortium. Nat
Genet 25:25–29
27. Al-Shahrour F, Minguez P, Vaquerizas JM, Conde L, Dopazo J
2005 BABELOMICS: a suite of web tools for functional annotation
and analysis of groups of genes in high-throughput experiments.
Nucleic Acids Res 33:W460–W464
28. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S,
Lehar J, Puigserver P, Carlsson E, Ridderstråle M, Laurila E, Hous-
tis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P,
Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC
2003 PGC-1-responsive genes involved in oxidative phosphoryla-
tion are coordinately downregulated in human diabetes. Nat Genet
34:267–273
29. Gualberto A 2010 Figitumumab (CP-751,871) for cancer therapy.
Expert Opin Biol Ther 10:575–585
30. Zhang H, Sachdev D, Wang C, Hubel A, Gaillard-Kelly M, Yee D
2009 Detection and downregulation of type I IGF receptor expres-
sion by antibody-conjugated quantum dots in breast cancer cells.
Breast Cancer Res Treat 114:277–285
31. Broussas M, Dupont J, Gonzalez A, Blaecke A, Fournier M, Cor-
vaïa N, Goetsch L 2009Molecular mechanisms involved in activity
Mol Endocrinol, September 2012, 26(9):1603–1616 mend.endojournals.org 1615
Downloaded from https://academic.oup.com/mend/article-abstract/26/9/1603/2614994
by IEO - European Institute of Oncology user
on 23 February 2018
of h7C10, a humanized monoclonal antibody, to IGF-1 receptor.
Int J Cancer 124:2281–2293
32. Belfiore A, Malaguarnera R 2011 The insulin receptor and cancer.
Endocr Relat Cancer 18:R125–R147
33. Sachdev D, Singh R, Fujita-Yamaguchi Y, Yee D 2006 Down-
regulation of insulin receptor by antibodies against the type I
insulin-like growth factor receptor: implications for anti-insulin-
like growth factor therapy in breast cancer. Cancer Res 66:2391–
2402
34. Polo S, Di Fiore PP 2006 Endocytosis conducts the cell signaling
orchestra. Cell 124:897–900
35. Martins AS, Ordóñez JL, Amaral AT, Prins F, Floris G, Debiec-
Rychter M, Hogendoorn PC, de Alava E 2011 IGF1R signaling in
Ewing sarcoma is shaped by clathrin-/caveolin-dependent endocy-
tosis. PloS one 6:e19846
36. Sorkin A, Goh LK 2009 Endocytosis and intracellular trafficking of
ErbBs. Exp Cell Res 315:683–696
37. Giudice J, Leskow FC, Arndt-Jovin DJ, Jovin TM, Jares-Erijman
EA 2011 Differential endocytosis and signaling dynamics of insulin
receptor variants IR-A and IR-B. J Cell Sci 124:801–811
38. Sacco A, Morcavallo A, Pandini G, Vigneri R, Belfiore A 2009
Differential signaling activation by insulin and insulin-like growth
factors I and II upon binding to insulin receptor isoform A. Endo-
crinology 150:3594–3602
39. Huang HJ, Angelo LS, Rodon J, SunM, Kuenkele KP, Parsons HA,
Trent JC, Kurzrock R 2011 R1507, an anti-insulin-like growth
factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ew-
ing’s sarcoma: convergence at the IGF/IGFR/Akt axis. PloS one
6:e26060
40. Gallagher EJ, LeRoith D 2011 Minireview: IGF, insulin, and can-
cer. Endocrinology 152:2546–2551
41. Hopkins A, Crowe PJ, Yang JL 2010 Effect of type 1 insulin-like
growth factor receptor targeted therapy on chemotherapy in human
cancer and the mechanisms involved. J Cancer Res Clin Oncol
136:639–650
42. Hixon ML, Paccagnella L, Millham R, Perez-Olle R, Gualberto A
2010 Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR
pathway. Rev Recent Clin Trial 5:189–208
43. Boucher J, Tseng YH, Kahn CR 2010 Insulin and insulin-like
growth factor-1 receptors act as ligand-specific amplitude modula-
tors of a common pathway regulating gene transcription. J Biol
Chem 285:17235–17245
44. Zha J, O’Brien C, Savage H, Huw LY, Zhong F, Berry L, Lewis
Phillips GD, Luis E, Cavet G, Hu X, Amler LC, Lackner MR 2009
Molecular predictors of response to a humanized anti-insulin-like
growth factor-I receptor monoclonal antibody in breast and colo-
rectal cancer. Mol Cancer Ther 8:2110–2121
45. Mukohara T, Shimada H, Ogasawara N, Wanikawa R, Shimo-
muraM,Nakatsura T, Ishii G, Park JO, Jänne PA, Saijo N,Minami
H 2009 Sensitivity of breast cancer cell lines to the novel insulin-like
growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is de-
pendent on the level of IRS-1 expression. Cancer Lett 282:14–24
46. Hendrickson AW,Haluska P 2009 Resistance pathways relevant to
insulin-like growth factor-1 receptor-targeted therapy. Curr Opin
Invest Drug 10:1032–1040
47. Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, Wan X,
Khanna C, Helman LJ 2008 Addiction to elevated insulin-like
growth factor I receptor and initial modulation of the AKTpathway
define the responsiveness of rhabdomyosarcoma to the targeting
antibody. Cancer Res 68:8039–8048
48. Baserga R 2009 Customizing the targeting of IGF-1 receptor. Fut
Oncol 5:43–50
49. Siegrist F, Ebeling M, Certa U 2011 The small interferon-induced
transmembrane genes and proteins. J Interf Cytok Res 31:183–197
50. Manara MC, Perdichizzi S, Serra M, Pierini R, Benini S, Hattinger
CM, Astolfi A, Bagnati R, D’Incalci M, Picci P, Scotlandi K 2005
The molecular mechanisms responsible for resistance to ET-743
(Trabectidin; Yondelis) in the Ewing’s sarcoma cell line, TC-71. Int
J Oncol 27:1605–1616
51. Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L,
Veldman-JonesM, Blakey DC, Tabrizi M, Jallal B, Trail PA, Coats
S, Bosslet K, Chang YS 2011 Dual IGF-I/II-neutralizing antibody
MEDI-573 potently inhibits IGF signaling and tumor growth. Can-
cer Res 71:1029–1040
1616 Garofalo et al. Resistance to Anti-IGF-IR Therapy Mol Endocrinol, September 2012, 26(9):1603–1616
Downloaded from https://academic.oup.com/mend/article-abstract/26/9/1603/2614994
by IEO - European Institute of Oncology user
on 23 February 2018
